B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

19.40 +0.06 (+0.31%)
Streaming Delayed Price Updated: 10:21 AM EST, Jan 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Legend Biotech Announces Appointment of Chief Medical Officer
From Legend Biotech
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Legend Biotech Establishes Strategic Advisory Board
From Legend Biotech
Via Business Wire
News headline image
Legend Biotech Reports Full-Year 2022 Results and Recent Highlights
From Legend Biotech
Via Business Wire
News headline image
Where Legend Biotech Stands With Analysts ↗
 
Via Benzinga
The Latest Analyst Ratings for Legend Biotech ↗
 
Via Benzinga
4 Analysts Have This to Say About Legend Biotech ↗
 
Via Benzinga
News headline image
7 Biotech Stocks to Buy for Breakthrough Treatments and Cures ↗
For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 29, 2023 ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2023 ↗
 
Via Benzinga
News headline image
Legend Biotech Announces Participation in Upcoming Investor Conferences
From Legend Biotech
Via Business Wire
News headline image
Legend Biotech Regains Compliance with NASDAQ Listing Rule 5250(c)(2)
From Legend Biotech
Via Business Wire
News headline image
Week In Review: HutchMed Announces $1.1 Billion Deal With Takeda For Colorectal Cancer Drug ↗
Shanghai’s HutchMed out-licensed global rights for a colorectal cancer therapy to Japan’s Takeda in a deal worth up to $1.13 billion, including $400 million upfront. In addition to the $1.13 billion,... 
Via Talk Markets
News headline image
Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI® (ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
From Legend Biotech
Via Business Wire
News headline image
Legend Biotech to Participate in the 41st Annual JP Morgan Healthcare Conference
From Legend Biotech
Via Business Wire
News headline image
Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China
From Legend Biotech
Via Business Wire
News headline image
Gracell Biotech Stock Has Over 100% Upside On Next-Gen CAR-T Platforms, Analyst Claims ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022 ↗
 
Via Benzinga
News headline image
Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer
From Legend Biotech
Via Business Wire
News headline image
Legend Biotech Announces Participation in Upcoming Investor Conferences
From Legend Biotech
Via Business Wire
News headline image
Legend Biotech Shares Updated Data from Comprehensive Cilta-Cel Clinical Development Program at ASH 2022
From Legend Biotech Corporation
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Carnival, Amazon, Iamgold And Other Big Gainers From Tuesday ↗
U.S. stocks closed higher on Monday, with the Dow Jones gaining more than 300 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
News headline image
Why Legend Biotech's Shares Jumped 14.2% On Tuesday ↗
The company presented news regarding early revenue figures for a multiple myeloma therapy it collaborated on. 
Via The Motley Fool
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022 ↗
Upgrades 
Via Benzinga
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
Via AB Newswire
News headline image
Why Quoin Pharmaceuticals Shares Jumped By More Than 44%; Here Are 57 Biggest Movers From Yesterday ↗
Gainers COMSovereign Holding Corp. (NASDAQ: COMS) shares jumped 170.1% to close at $0.1194 on Tuesday after gaining 4% on Monday. 
Via Benzinga
News headline image
CARVYKTI™ (ciltacabtagene autoleucel) Receives Approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
From Legend Biotech Corporation
Via Business Wire
News headline image
Legend Biotech to Host 2022 R&D Day on Monday, October 3, 2022
From Legend Biotech Legend Biotech Corporation
Via Business Wire
News headline image
No Early Relief for JW Therapeutics from Cancer Wonder Drug ↗
Key Takeaways: JW Therapeutics prices its new cancer therapy at around a million yuan, with the high production costs hard to bring down.  Large-scale market expansion is not going to be easy  The... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.